Equities Analysts Offer Predictions for ANIP Q3 Earnings

Key Points

• HC Wainwright analysts have raised their Q3 2025 EPS forecast for ANI Pharmaceuticals to $1.21 from $1.19, maintaining a "Buy" rating and a target price of $121.00.
• ANI Pharmaceuticals reported Q2 earnings of $1.80 EPS, exceeding estimates by $0.38, with revenues of $211.37 million, representing a 53.2% year-over-year increase.
• Insider sales were notable, with COO Muthusamy Shanmugam selling 52,990 shares for approximately $4.62 million, reflecting a 9.06% decrease in ownership.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) - Stock analysts at HC Wainwright lifted their Q3 2025 earnings per share estimates for shares of ANI Pharmaceuticals in a research report issued to clients and investors on Wednesday, September 17th. HC Wainwright analyst B. Folkes now forecasts that the specialty pharmaceutical company will post earnings per share of $1.21 for the quarter, up from their previous estimate of $1.19. HC Wainwright currently has a "Buy" rating and a $121.00 target price on the stock. The consensus estimate for ANI Pharmaceuticals' current full-year earnings is $3.86 per share. HC Wainwright also issued estimates for ANI Pharmaceuticals' Q4 2025 earnings at $1.70 EPS, FY2025 earnings at $5.73 EPS and FY2026 earnings at $6.53 EPS.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.38. The business had revenue of $211.37 million during the quarter, compared to analysts' expectations of $187.18 million. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The business's quarterly revenue was up 53.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.02 EPS.

Other equities research analysts have also issued research reports about the company. Zacks Research raised ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 21st. Wall Street Zen raised ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 16th. Guggenheim boosted their price objective on ANI Pharmaceuticals from $86.00 to $114.00 and gave the company a "buy" rating in a research note on Monday, September 8th. Truist Financial boosted their price objective on ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a research note on Monday, August 11th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $93.00.

ANI Pharmaceuticals Stock Down 0.9%

Shares of NASDAQ ANIP traded down $0.86 during midday trading on Thursday, hitting $95.93. 290,218 shares of the company's stock were exchanged, compared to its average volume of 376,652. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $99.50. The company has a market cap of $2.08 billion, a PE ratio of -124.58 and a beta of 0.63. The firm's fifty day simple moving average is $83.32 and its 200-day simple moving average is $71.38.

Insiders Place Their Bets

In other news, SVP Chad Gassert sold 20,000 shares of the business's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $86.97, for a total value of $1,739,400.00. Following the transaction, the senior vice president owned 173,226 shares of the company's stock, valued at approximately $15,065,465.22. The trade was a 10.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jeanne Thoma sold 21,540 shares of the business's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $89.15, for a total value of $1,920,291.00. Following the completion of the transaction, the director directly owned 23,405 shares in the company, valued at approximately $2,086,555.75. The trade was a 47.93% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 413,830 shares of company stock valued at $36,495,294. 12.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Advisors Asset Management Inc. acquired a new position in shares of ANI Pharmaceuticals in the first quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd grew its holdings in ANI Pharmaceuticals by 4,636.4% during the second quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company's stock worth $34,000 after acquiring an additional 510 shares during the period. Newbridge Financial Services Group Inc. grew its holdings in ANI Pharmaceuticals by 200.0% during the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company's stock worth $39,000 after acquiring an additional 400 shares during the period. State of Wyoming acquired a new position in ANI Pharmaceuticals during the second quarter worth $50,000. Finally, National Bank of Canada FI acquired a new position in ANI Pharmaceuticals during the first quarter worth $79,000. Institutional investors and hedge funds own 76.05% of the company's stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.